UPDATE: March 5, 2020: The U. S. Senate voted Thursday afternoon to approve the spending package, which now awaits President Donald Trump's signature.
- The House of Representatives approved an $8.3 billion funding bill Wednesday for ongoing efforts to respond to COVID-19, with 11 U.S. deaths related to the disease reported as of Thursday morning. The Senate is scheduled to vote on the legislation Thursday with passage likely.
- The package allocates about $6.5 billion to the Department of Health and Human Services, including $3.1 billion for medical supplies like masks as well as research into treatments and vaccines.
- Money will also go to the Centers for Disease Control and Prevention to help local and state governments with testing and containment efforts. Some of the $836 million to the National Institutes of Health is marked for training "to prevent and reduce exposure of hospital employees" and others at risk of exposure through work duties.
The amount in the funding bill making its way through Congress dwarfs the original White House request of $2.5 billion from last week. The number of coronavirus cases internationally and in the U.S. has continued to increase, with more than 95,000 confirmed globally. Several recent U.S. cases have indicated community spread, including in major metropolitan areas like Seattle and New York City.
The funding bill provides more than $2 billion for the Biomedical Advanced Research and Development Authority for vaccine development and requires that vaccines, therapeutics or diagnostics developed using taxpayer money be "available for purchase by the Federal government at a fair and reasonable price." It also allows the HHS secretary to ensure those products would be "affordable in the commercial market."
Multiple pharmaceutical companies have announced COVID-19 vaccine developments are underway, including Johnson & Johnson and Sanofi, which are partnering with BARDA for their efforts. While the pharmas say they will move as quickly as possible, experts say a realistic development process would put a vaccine 12 to 18 months away at the earliest.
Also Wednesday, lab testing companies including LabCorp, Quest Diagnostics and Thermo Fisher met with Trump administration officials who encouraged them to ramp up efforts regarding the novel coronavirus.
Pence, who is currently leading the administration's response effort, said 2,500 kits with more than 1.5 million tests are now available to hospitals that have requested them. Earlier this week, the Centers for Disease Control and Prevention adjusted its guidance to say patients need only their doctor's approval to be tested.
Pence said the objective is to make sure the tests are broadly available to the American public. "We want to make sure the American people can go to their doctor, can go to the local MedCheck or CVS, and obtain access to coronavirus" tests, he said.
Hospitals will be disappointed the legislation does not address provider reimbursement for treatment of coronavirus patients who are uninsured. The American Hospital Association on Tuesday called for HHS to consider using a national disaster program for such treatment. It generally pays providers at 110% of Medicare rates.
Still, hospitals responded positively to the funding. The Federation of American Hospitals said the bill provides essential assistance to those on the front lines.
Hospitals throughout the country have been scrambling to prepare isolation areas and stock up on personal protective equipment like masks and gloves as the virus continues to spread. HHS said Wednesday it plans to buy 500 million N95 masks over the next 18 months for the Strategic National Stockpile. Vice President Mike Pence is slated to visit mask manufacturer 3M in Minnesota on Thursday.
Earlier this week, FDA granted a CDC request to allow healthcare personnel to use masks not regulated by the FDA for health settings during the emergency.
Additionally, the legislation grants HHS the authority to temporarily waive or modify certain Medicare requirements like geography and site origination for telehealth services provided during the emergency period, an adjustment providers had requested.
The loosened restrictions for telehealth reimbursement will be welcome news to those pushing for more virtual visits to keep potentially infected people from spreading the virus.